Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape

Journal of Clinical Oncology

Volumn 33, Issue 27, 2015, Pages 2986-2998

  Gajjar, Amar ^a   Bowers, Daniel C ^b   Karajannis, Matthias A ^c   Leary, Sarah ^d   Witt, Hendrik ^e   Gottardo, Nicholas G ^f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE;

ATYPICAL TERATOID RHABDOID TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CHILDHOOD CANCER; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME MUTATION; CLINICAL PROTOCOL; DNA METHYLATION; EPENDYMOMA; EVENT FREE SURVIVAL; GENE MUTATION; GENOMICS; GLIOMA; HUMAN; INTERNATIONAL COOPERATION; MEDULLOBLASTOMA; MOLECULAR GENETICS; NEUROECTODERM TUMOR; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PONTINE GLIOMA; PRIORITY JOURNAL; RARE DISEASE; REVIEW; ADOLESCENT; BRAIN NEOPLASMS; CHILD; COOPERATION; GENETIC SCREENING; GENETICS; INFANT; INTERDISCIPLINARY COMMUNICATION; MASS COMMUNICATION; MORTALITY; ONCOLOGY; ONSET AGE; PEDIATRICS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRESCHOOL CHILD; SURVIVOR; TIME; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; GENETIC TESTING; GENOMICS; HUMANS; INFANT; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; PEDIATRICS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942250025     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.9217     Document Type: Review

References (119)

1. Pui CH, Gajjar AJ, Kane JR, et al: Challenging issues in pediatric oncology. Nat Rev Clin Oncol 8:540-549, 2011
2. Northcott PA, Shih DJ, Peacock J, et al: Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488:49-56, 2012
3. Ellison DW, Kocak M, Dalton J, et al: Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400- 1407, 2011
4. Gajjar AJ, Robinson GW: Medulloblastoma: Translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 11:714-722, 2014
5. Taylor MD, Northcott PA, Korshunov A, et al: Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123:465-472, 2012
6. Northcott PA, Tuka JT, Taylor MD: Genomics of medulloblastoma: From Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 28:E6, 2010
7. Northcott PA, Jones DT, Kool M, et al: Medulloblastomics: The end of the beginning. Nat Rev Cancer 12:818-834, 2012
8. Gibson P, Tong Y, Robinson G, et al: Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095-1099, 2010
9. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006
10. Ellison DW, Onilude OE, Lindsey JC, et al: beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005
11. Robinson G, Parker M, Kranenburg TA, et al: Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43-48, 2012
12. Pugh TJ, Weeraratne SD, Archer TC, et al: Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488: 106-110, 2012
13. Jones DT, Jäger N, Kool M, et al: Dissecting the genomic complexity underlying medulloblastoma. Nature, 488:100-105, 2012
14. Zhukova N, Ramaswamy V, Remke M, et al: Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31:2927- 2935, 2013
15. Kool M, Korshunov A, Remke M, et al: Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol 123:473-484, 2012
16. Kool M, Jones DT, Jäger N, et al: Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25:393-405, 2014
17. Rutkowski S, Bode U, Deinlein F, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978-986, 2005
18. Kool M, Korshunov A, Pfister SM: Update on molecular and genetic alterations in adult medulloblastoma. Memo 5:228-232, 2012
19. Northcott PA, Lee C, Zichner T, et al: Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511:428-434, 2014
20. Northcott PA, Nakahara Y, Wu X, et al: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472, 2009
21. Shih DJ, Northcott PA, Remke M, et al: Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32:886-896, 2014
22. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999
23. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24: 4202-4208, 2006
24. Tarbell NJ, Friedman H, Polkinghorn WR, et al: High-risk medulloblastoma: A Pediatric Oncology Group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31:2936-2941, 2013
25. Rutkowski S, von Hoff K, Emser A, et al: Survival and prognostic factors of early childhood medulloblastoma: An international meta-analysis. J Clin Oncol 28:4961-4968, 2010
26. Rudin CM, Hann CL, Laterra J, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178, 2009
27. Gajjar A, Stewart CF, Ellison DW, et al: Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study. Clin Cancer Res 19:6305-6312, 2013
28. Kim J, Aftab BT, Tang JY, et al: Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23:23-34, 2013
29. Morfouace M, Shelat A, Jacus M, et al: Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25:516-529, 2014
30. Bandopadhayay P, Bergthold G, Nguyen B, et al: BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 20:912-925, 2014
31. Tang Y, Gholamin S, Schubert S, et al: Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 20:732-740, 2014
32. Schwartzentruber J, Korshunov A, Liu XY, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231, 2012
33. Sturm D, Witt H, Hovestadt V, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437, 2012
34. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al: Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46:462-466, 2014
35. Wu G, Diaz AK, Paugh BS, et al: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444-450, 2014
36. Buczkowicz P, Hoeman C, Rakopoulos P, et al: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451-456, 2014
37. Taylor KR, Mackay A, Truffaux N, et al: Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46:457-461, 2014
38. Sturm D, Bender S, Jones DT, et al: Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92-107, 2014
39. Korshunov A, Ryzhova M, Hovestadt V, et al: Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129:669-678, 2015
40. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
41. Cohen KJ, Pollack IF, Zhou T, et al: Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group. Neuro Oncol 13:317-323, 2011
42. Wolff JE, Driever PH, Erdlenbruch B, et al: Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: Results of the HIT-GBM-C protocol. Cancer 116: 705-712, 2010
43. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J Clin Oncol 21:1581-1591, 2003
44. Cohen KJ, Heideman RL, Zhou T, et al: Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol 13:410-416, 2011
45. Bradley KA, Zhou T, McNall-Knapp RY, et al: Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A children's oncology group phase 2 study. Int J Radiat Oncol Biol Phys 85:e55-e60, 2013
46. Ater JL, Zhou T, Holmes E, et al: Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the Children's Oncology Group. J Clin Oncol 30:2641-2647, 2012
47. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
48. Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
49. Narayana A, Kunnakkat S, Chacko-Mathew J, et al: Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 12:985-990, 2010
50. Gururangan S, Fangusaro J, Poussaint TY, et al: Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas: A Pediatric Brain Tumor Consortium study. Neuro Oncol 16: 310-317, 2014
51. Dhanak D, Jackson P: Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun 455:58-69, 2014
52. Dawson MA Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell 150:12-27, 2012
53. Robinson GW, Orr BA, Gajjar A: Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258, 2014
54. Pfister S, Janzarik WG, Remke M, et al: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739-1749, 2008
55. Bar EE, Lin A, Tihan T,, et al: Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67:878-887, 2008
56. Sievert AJ, Jackson EM, Gai X, et al: Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 19:449-458, 2009
57. Lin A, Rodriguez FJ, Karajannis MA, et al: BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 71:66-72, 2012
58. Forshew T, Tatevossian RG, Lawson AR, et al: Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218:172-181, 2009
59. Hawkins C, Walker E, Mohamed N, et al: BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17:4790-4798, 2011
60. Jacob K, Albrecht S, Sollier C, et al: Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 101:722-733, 2009
61. Cin H, Meyer C, Janzarik WG, et al: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 121:763-774, 2011
62. Rodriguez EF, Scheithauer BW, Giannini C, et al: PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 121:407-420, 2011
63. Schindler G, Capper D, Meyer J, et al: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405, 2011
64. Jones DT, Kocialkowski S, Liu L, et al: Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28:2119-2123, 2009
65. Eisenhardt AE, Olbrich H, Röring M, et al: Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129:2297-2303, 2011
66. Korshunov A, Meyer J, Capper D, et al: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118:401-405, 2009
67. Buccoliero AM, Castiglione F, Degl'Innocenti DR, et al: IDH1 mutation in pediatric gliomas: Has it a diagnostic and prognostic value? Fetal Pediatr Pathol 31:278-282, 2012
68. Wisoff JH, Sanford RA, Heier LA, et al: Primary neurosurgery for pediatric low-grade gliomas: A prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 68:1548- 1554, 2011; discussion 1554-1555
69. Merchant TE, Kun LE, Wu S, et al: Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 27:3598-3604, 2009
70. Packer RJ, Lange B, Nicholson HS, et al: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850-856, 1993
71. Müller K, Gnekow A, Falkenstein F, et al: Radiotherapy in pediatric pilocytic astrocytomas: A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol 189:647-655, 2013
72. Bandopadhayay P, Bergthold G, London WB, et al: Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61:1173- 1179, 2014
73. Fisher PG, Tihan T, Goldthwaite PT, et al: Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 51:245-250, 2008
74. Gnekow AK, Falkenstein F, von Hornstein S, et al: Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for lowgrade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 14:1265-1284, 2012
75. Gajjar A, Sanford RA, Heideman R, et al: Low-grade astrocytoma: A decade of experience at St Jude Children's Research Hospital. J Clin Oncol 15:2792-2799, 1997
76. Karajannis MA, Legault G, Fisher MJ, et al: Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 16:1408-1416, 2014
77. Sievert AJ, Lang SS, Boucher KL, et al: Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 110: 5957-5962, 2013
78. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
79. Franz DN, Leonard J, Tudor C, et al: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498, 2006
80. Krueger DA, Care MM, Agricola K, et al: Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80: 574-580, 2013
81. Yalon M, Rood B, MacDonald TJ, et al: A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 60:71-76, 2013
82. Kieran MW, Yao X, Macy M, et al: Prospective multi-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. Pediatr Blood Cancer, SIOP 2013 Scientific Programme 60:O-0068, 2013
83. McGuire CS, Sainani KL, Fisher PG: Incidence patterns for ependymoma: A Surveillance, Epidemiology, and End Results study. J Neurosurg 110:725-729, 2009
84. Gatta G, Botta L, Rossi S, et al: Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5 - a population-based study. Lancet Oncol 15:35-47, 2014
85. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
86. Ellison DW, Kocak M, Figarella-Branger D, et al: Histopathological grading of pediatric ependymoma: Reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7, 2011
87. Johnson RA, Wright KD, Poppleton H, et al: Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632-636, 2010
88. Witt H, Mack SC, Ryzhova M, et al: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143-157, 2011
89. Wani K, Armstrong TS, Vera-Bolanos E,, et al: A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123: 727-738, 2012
90. Hoffman LM, Donson AM, Nakachi I, et al: Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 127:731-745, 2014
91. Mack SC, Witt H, Piro RM, et al: Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445-450, 2014
92. Parker M, Mohankumar KM, Punchihewa C, et al: C11orf95-RELA fusions drive oncogenic NFkappaB signalling in ependymoma. Nature 506:451- 455, 2014
93. Pajtler KW, Witt H, Sill M, et al: Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728-743, 2015
94. Atkinson JM, Shelat AA, Carcaboso AM, et al: An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-399, 2011
95. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002
96. Rorke LB, Packer R, Biegel J: Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol 24:21-28, 1995
97. von Hoff K, Hinkes B, Dannenmann-Stern E, et al: Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer 57:978-985, 2011
98. Athale UH, Duckworth J, Odame I, et al: Childhood atypical teratoid rhabdoid tumor of the central nervous system: A meta-analysis of observational studies. J Pediatr Hematol Oncol 31:651-663, 2009
99. Lafay-Cousin L, Hawkins C, Carret AS, et al: Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 48:353-359, 2012
100. Pfister SM, Korshunov A, Kool M, et al: Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 120:553-566, 2010
101. Biegel JA, Zhou JY, Rorke LB, et al: Germline and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74-79, 1999
102. Slavc I, Chocholous M, Leiss U, et al: Atypical teratoid rhabdoid tumor: Improved long-term survival with an intensive multimodal therapy and delayed radiotherapy - The Medical University of Vienna Experience, 1992 to 2012. Cancer Med 3:91- 100, 2014
103. Tekautz TM, Fuller CE, Blaney S, et al: Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23:1491-1499, 2005
104. Geyer JR, Sposto R, Jennings M, et al: Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 23:7621-7631, 2005
105. Grundy RG, Wilne SH, Robinson KJ, et al: Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: Results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer, 46:120-133, 2010
106. Chi SN, Zimmerman MA Yao X, et al: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385-389, 2009
107. Gardner SL, Asgharzadeh S, Green A, et al: Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 51:235-240, 2008
108. Picard D, Miller S, Hawkins CE, et al: Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: An integrative genomic analysis. Lancet Oncol 13:838- 848, 2012
109. Li M, Lee KF, Lu Y, et al: Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16:533-546, 2009
110. Korshunov A, Ryzhova M, Jones DT, et al: LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124:875-881, 2012
111. Korshunov A, Sturm D, Ryzhova M, et al: Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 128:279-289, 2014
112. Spence T, Perotti C, Sin-Chan P, et al: A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol 16:62-71, 2014
113. Fangusaro JR, Jubran RF, Allen J, et al: Brainstem primitive neuroectodermal tumors (bst- PNET): Results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue. Pediatr Blood Cancer 50:715-717, 2008
114. Reddy AT, Janss AJ, Phillips PC, et al: Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88:2189-2193, 2000
115. Gerber NU, von Hoff K, Resch A, et al: Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. Int J Radiat Oncol Biol Phys 89:863-871, 2014
116. Cohen BH, Zeltzer PM, Boyett JM, et al: Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial. J Clin Oncol 13:1687-1696, 1995
117. Perreault S, Lober RM, Carret AS, et al: Relapse patterns in pediatric embryonal central nervous system tumors. J Neurooncol 115:209-215, 2013
118. Chintagumpala M, Hassall T, Palmer S, et al: A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 11:33-40, 2009
119. Gottardo NG, Hansford SJ, McGlade JP, et al: Medulloblastoma down under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 127:189-201, 2014